Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Tonix Pharmaceuticals Holding Corp. (TNXP : NSDQ)
 
 • Company Description   
Tonix Pharmaceuticals Holding Corp. is a specialty pharmaceutical company focused on developing new pharmaceutical products for CNS conditions. The Company develops therapies for disorders that include fibromyalgia syndrome and post-traumatic stress disorder. Its lead product candidates include TNX-102, for the management of fibromyalgia syndrome and TNX-105 to treat symptoms of post-traumatic stress disorder. Tonix Pharmaceuticals Holding Corp. is headquartered in New York.

Number of Employees: 57

 
 • Price / Volume Information   
Yesterday's Closing Price: $42.36 Daily Weekly Monthly
20 Day Moving Average: 623,279 shares
Shares Outstanding: 7.36 (millions)
Market Capitalization: $311.65 (millions)
Beta: 2.05
52 Week High: $84.56
52 Week Low: $6.76
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 22.64% 18.05%
12 Week 169.64% 126.80%
Year To Date 28.44% 20.28%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
26 MAIN STREET SUITE 101
-
CHATHAM,NJ 07928
USA
ph: 862-799-8599
fax: 212-923-5700
investor.relations@tonixpharma.com http://www.tonixpharma.com
 
 • General Corporate Information   
Officers
Seth Lederman - Chief Executive Officer; President and Director
Bradley Saenger - Chief Financial Officer
Richard Bagger - Director
Margaret Smith Bell - Director
David Grange - Director

Peer Information
Tonix Pharmaceuticals Holding Corp. (GSAC)
Tonix Pharmaceuticals Holding Corp. (CASI)
Tonix Pharmaceuticals Holding Corp. (ALCD.)
Tonix Pharmaceuticals Holding Corp. (OMNN)
Tonix Pharmaceuticals Holding Corp. (CGPI.)
Tonix Pharmaceuticals Holding Corp. (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 890260839
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/15/25
Share - Related Items
Shares Outstanding: 7.36
Most Recent Split Date: 2.00 (0.01:1)
Beta: 2.05
Market Capitalization: $311.65 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-3.32 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-12.93 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.51
Price/Cash Flow: -
Price / Sales: 31.04
EPS Growth
vs. Year Ago Period: 99.51%
vs. Previous Quarter: 70.93%
Sales Growth
vs. Year Ago Period: -2.14%
vs. Previous Quarter: -5.93%
ROE
06/30/25 - -
03/31/25 - -120.96
12/31/24 - -142.89
ROA
06/30/25 - -
03/31/25 - -101.28
12/31/24 - -112.21
Current Ratio
06/30/25 - -
03/31/25 - 12.31
12/31/24 - 6.50
Quick Ratio
06/30/25 - -
03/31/25 - 11.64
12/31/24 - 6.04
Operating Margin
06/30/25 - -
03/31/25 - -1,313.87
12/31/24 - -1,288.25
Net Margin
06/30/25 - -
03/31/25 - -1,313.87
12/31/24 - -1,288.25
Pre-Tax Margin
06/30/25 - -
03/31/25 - -1,313.87
12/31/24 - -1,288.25
Book Value
06/30/25 - -
03/31/25 - 28.03
12/31/24 - 31.82
Inventory Turnover
06/30/25 - -
03/31/25 - 0.83
12/31/24 - 0.81
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.03
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 3.24
 

Powered by Zacks Investment Research ©